Doctorate, at School of Pharmacy, China.
Dr. Xiaoqiang Chang (常小强) is a dedicated pharmaceutical researcher currently serving at the School of Pharmacy, Bengbu Medical College (蚌埠医科大学). He earned his Ph.D. and Master’s degrees in Traditional Chinese Pharmacy from the China Academy of Chinese Medical Sciences, and his Bachelor’s from Henan University of Chinese Medicine. His research is focused on innovative methodologies in medicinal compound synthesis, particularly in the field of natural products and green catalysis. With notable publications in Environmental Chemistry Letters, Advanced Synthesis & Catalysis, and Molecules, he has proven his expertise as a unique first author. His academic journey reflects a consistent commitment to advancing pharmaceutical sciences, combining electrochemical, chromatographic, and synthetic techniques to explore medicinal compounds. Dr. Chang also holds a Chinese patent on diphenyldiazepine derivatives. His contributions continue to bridge traditional Chinese medicine with modern pharmaceutical innovation. 🌿⚗️📚
Professional Profile
ORCID
🎓 Education
Dr. Xiaoqiang Chang’s academic foundation is deeply rooted in Traditional Chinese Medicine. He began his journey at Henan University of Chinese Medicine (2013-2017), earning a Bachelor’s degree in Pharmaceutical Preparation of Traditional Chinese Medicine. Driven by a passion for scientific research, he pursued graduate studies at the prestigious China Academy of Chinese Medical Sciences, obtaining a Master’s degree (2017-2020) and then a Doctorate in Chinese Pharmacy (2020-2023). During his doctoral training, Dr. Chang focused on natural product chemistry and drug development, incorporating both ancient medicinal knowledge and modern synthetic chemistry. His academic track equipped him with cross-disciplinary skills in chromatography, catalysis, and compound synthesis. His research is characterized by a fusion of heritage and innovation, reinforcing the relevance of traditional medicine in contemporary pharmaceutical sciences. 🎓🔬📖
💼 Experience
Dr. Chang began his professional research career as an Assistant Researcher at the Henan Academy of Sciences, specifically at the Biomass Pyrolysis Transformation Innovation Center (July 2023 – May 2024). Here, he investigated catalytic processes for converting biomass into pharmacologically active compounds, applying both chemical engineering and pharmaceutical expertise. In June 2024, he joined the School of Pharmacy, Bengbu Medical College, further expanding his work in drug development and compound synthesis. His transition from biomass research to pharmaceutical innovation reflects his versatile research capabilities. Despite not having postdoctoral experience, Dr. Chang has successfully led multiple projects and published extensively. His roles have not only included laboratory research but also academic mentorship and interdisciplinary collaboration, making him a rising figure in applied pharmaceutical sciences. 🔍🏥🧪
🔬 Research Interest
Dr. Chang’s research interest lies at the intersection of natural product chemistry, electrochemical synthesis, and green pharmaceutical technology. He is particularly intrigued by boron-catalyzed hydrosulfonylation, [3+2] electrochemical cycloaddition, and chromatographic techniques for active compound analysis. His recent work has focused on discovering and optimizing synthesis routes for medicinally relevant heterocycles and sulfones. Dr. Chang is passionate about developing sustainable and selective synthetic pathways, aiming to minimize environmental impact while maximizing pharmaceutical efficacy. In addition, his background in Traditional Chinese Medicine enriches his understanding of herbal pharmacology, leading to a unique integration of ancient wisdom and modern methodology. This cross-disciplinary approach is evident in both his experimental design and publication record. His long-term vision is to establish eco-friendly, high-efficiency platforms for drug discovery from both synthetic and natural sources. 🌱🧬⚙️
🏆 Awards
Although Dr. Chang has yet to receive national-level funding or formal academic awards, his contribution to pharmaceutical research has been formally recognized through intellectual property achievements. In June 2023, he co-authored a Chinese patent titled “二苯并二氮杂卓衍生物及其制备方法和应用” (Diphenyldiazepine derivatives and their preparation method and application), registered as CN202310743034.9. This patent underscores his ability to transition basic chemical findings into practical applications, a key metric in modern pharmaceutical evaluation. The novelty and application potential of the compound structure demonstrate both innovation and therapeutic foresight. While still early in his career, Dr. Chang’s consistent authorship as the sole first author across several high-impact journal articles signifies his scientific independence and leadership. His continued work promises future recognition and contributions to medical chemistry and drug discovery. 🧪📜🚀
📚 Top Noted Publications
1.Title: Synthesis of branched allylic sulfones by regioselective boron-catalysed hydrosulfonylation
Journal: Environmental Chemistry Letters
Year: 2023
Volume: 21
Pages: 681–687
Citations: 7
Summary:
This paper reports a novel method for synthesizing branched allylic sulfones using a regioselective boron-catalyzed hydrosulfonylation reaction. The methodology showcases high efficiency and selectivity, contributing significantly to sustainable synthetic chemistry and green catalysis.
2.Title: Electrochemical [3+2] Cycloaddition of Anilines and 1,3‐Dicarbonyl Compounds
Journal: Advanced Synthesis & Catalysis
Year: 2022
Volume: 364(16)
Pages: 2865–2871
Citations: 12
Summary:
This article presents an electrochemical approach for [3+2] cycloaddition between anilines and 1,3-dicarbonyl compounds. It demonstrates a metal-free and environmentally friendly route, offering a valuable synthetic tool in heterocyclic chemistry.
3.Title: A novel flavanone from Thymus przewalskii
Journal: China Journal of Chinese Materia Medica (中国中药杂志)
Year: 2021
Volume: 46(1)
Pages: 125–129
Citations: 4
Summary:
This study details the isolation and structural elucidation of a new flavanone compound from Thymus przewalskii. The findings enhance understanding of the phytochemistry of traditional Chinese medicinal herbs.
4.Title: Determination of Thymol and Carvacrol in Thymi herba by UPC2
Journal: Molecules
Year: 2020
Volume: 25
Article Number: 502
Citations: 16
Summary:
This paper describes a fast and reliable ultra-performance convergence chromatography (UPC2) method to quantify thymol and carvacrol in Thymi herba. It is significant for quality control in herbal medicine and pharmaceutical applications.
5.Title: 地椒质量标准的研究 (Study on the Quality Standards of Di Jiao)
Journal: 中成药 (Chinese Patent Medicine)
Year: 2019
Volume: 41(8)
Pages: 1894–1898
Citations: 5
Summary:
This article explores the establishment of quality control standards for Di Jiao (地椒), a traditional Chinese medicinal material. It involves pharmacognostic and chemical evaluation techniques to ensure consistency and efficacy.
Conclusion
Dr. Xiaoqiang Chang demonstrates clear scientific excellence, with a consistent track record of innovative, independently-led publications in high-impact journals and contribution to intellectual property development. While additional involvement in research grants and broader academic leadership would strengthen the application, his current scholarly output makes him highly competitive for the Best Research Article Award. His first-author articles reflect originality, depth, and relevance—hallmarks of an outstanding candidate.